Idiopathic Parkinson Disease, Primary Parkinsonism
Conditions
Brief summary
The purpose of clinical trials is to evaluate safety and tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells as a treatment for Patients with Parkinson's disease.
Detailed description
This study is phase I/II clinical trials which is accessible to those involved in the study and conducted by only Bundang CHA hospital. The progress of the clinical trails is reported to and evaluated by Data monitoring committee before the enrolment of next human subject.
Interventions
DRUGMesencephalic Neuronal Precursor Cells
All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
Sponsors
Bundang CHA Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Female patients with idiopathic or primary Parkinson's disease 2. Hoehn and Yare (HY) stage III or IV 3. more than 33% improvement Part III UPDRS score after one injection of levodopa in the morning 4. Patients aged less than 70 5. Great decrease of dopamine uptake in putamen, particularly posterior part, in Positron emission tomograph(PET) before surgery
Exclusion criteria
1. Atypical or secondary parkinsonism 2. Medical history of severe depression with Beck Depression Inventory(BDI) scores greater than 30 3. Psychological disorders (illusion, delusion, schizophrenia) 4. Dementia with K-MMSE(Korean mini-mental state examination) scores less than 24 5. Epilepsy 6. Medial history of brain surgery 7. Medical history of other brain diseases 8. Hemorrhagic tendency 9. Severe internal diseases such as poor general condition, hypertension, chronic respiratory disease, ischemic heart disease, cancer 10. Experience of participating in clinical trial within 30 days 11. Female patients who have the chances of getting pregnant during clinical trial and do not use the approved birth controls 12. Pregnant or lactating women 13. Patients who are not considered to be eligible to participate in clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence or absence of cancer foramtion and infection | 5 years | If not included in the following criteria, the cells are are considered to be safe and tolerable. * Cells with grade 3 or more in NCI grading system * Cells contaminated with infectious materials * Cells with risk of cancer formation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Detection of positron emission in Putamen using Positron emission tomograph(PET) | 5 years | In pet analysis, putamen activity is investigated via radioactivity before cell transplantation and 12,24,36,48,60 months after the treatment. |
| Dyskinesia scale scores(CAPSIT-PD) | 5 years | Overall inspection was carried out before transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, 60 months after the treatment for determining whether the cells have therapeutic effects. |
| Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test | 5 years | Comprehensive clinical assessment for examining the improvements in self reporting and timed testing before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment:Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test. |
| Score of activity of daily living (ADL) scale | 5 years | Comprehensive clinical assessment for examining the improvements in activity of daily living before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. |
| Score of Korean mini-mental examination (K-MMSE) | 5 years | Comprehensive clinical assessment for examining the improvements in mental state before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. |
| Score of Unified Parkinson's Disease Rating Scale (UPDRS) | 5 years | UPDRS, most commonly used, is designed to assess the severity of parkinson's disease, making the quantitative measurement of the extent. Part III of UPDRS corresponds to motor evaluation and is the most reliable for detecting symptomatic progression. UPDRS improvement ratio(%) = ((the value of UPDRS before surgery - the value of UPDRS after surgery) / (the value of UPDRS before surgery)) X 100 |
| Satisfaction score with patient questionnaire | 5 years | Measure of patient satisfaction before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. |
| Dopaminergic drug dose | 5 years | Measure of dopaminergic drug dose before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. |
| Tremor, postural instability, motor dysfunction, gait disturbance | 5 years | Using video recording, assessment for symptoms such as tremor, postural instability, motor dysfunction and gait disturbance before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. |
| Assessing the extent of recovery with patient's diary | 5 years | Assessing the extent of recovery based on patient's diary before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. |
| Motor fluctuation scale scores | 5 years | Comprehensive clinical assessment for identifying the presence of motor fluctuation symptoms before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. |
Countries
South Korea
Contacts
Primary ContactSang Sup Chung, M.D., Ph.D.
Backup ContactJoo pyung Kim, M.D., Ph.D.
Outcome results
None listed